Portola Pharmaceuticals
Therapeutics for acute and chronic cardiovascular, and autoimmune and inflammatory diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD1.9b (Public information from May 2020)
San Francisco California (HQ)
Financials
Estimates*
EUR | 2015 | 2016 | 2017 | 2018 | 2019 |
---|---|---|---|---|---|
R&D budget | 184m | 234m | 168m | 188m | 111m |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$21.0m | Series A | ||
$46.0m | Series B | ||
$70.0m | Series C | ||
$60.1m | Series C | ||
$60.1m | Series C | ||
$89.0m | Series D | ||
N/A | $9.0m | Early VC | |
N/A | N/A | IPO | |
* | N/A | $100m | Post IPO Equity |
* | N/A | $150m | Post IPO Equity |
* | N/A | $349m | Post IPO Equity |
* | $125m | Post IPO Debt | |
* | N/A | $259m | Post IPO Equity |
* | $1.4b Valuation: $1.4b | Acquisition | |
Total Funding | CAD484m |
Related Content
Recent News about Portola Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.